Coldstream Capital Management’s Regenxbio RGNX Stock Holding History

Coldstream Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-81	Closed	-$580	–	2841
2025 Q1	$580	Buy	+81	New	+$603	﹤0.01%	3313

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Coldstream Capital Management's RGNX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Regenxbio (RGNX) in Q2 2025, closing a stake of 81 shares — an estimated $580 sold.

Coldstream Capital Management first reported a position in RGNX in Q1 2025 and held it in 1 quarter. The position peaked at $580 in Q1 2025. 159 funds tracked by Wall St. Rank hold RGNX as of Q2 2025.

Coldstream Capital Management reported no remaining Regenxbio position as of Q2 2025 after selling out during the quarter.
Coldstream Capital Management sold 81 Regenxbio shares in Q2 2025, an estimated $580.
Coldstream Capital Management first reported a position in Regenxbio in Q1 2025 and held it in 1 quarter.
Coldstream Capital Management's Regenxbio position peaked at $580 in Q1 2025.
159 funds tracked by Wall St. Rank held Regenxbio as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.